Product Description
Memo Therapeuitcs AG’s (“MTx”) lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. MTx’ pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical. (Sourced from: https://memo-therapeutics.com/pipeline.html)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: Fast Track - Renal Transplant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Memo Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Kidney Transplant
Phase 1: Kidney Diseases|Opportunistic Infections|Polyomavirus Infections|Renal Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SAFE KIDNEY II | P3 |
Recruiting |
Kidney Transplant |
2024-11-24 |
|
| SAFE KIDNEY I | P1 |
Completed |
Polyomavirus Infections|Opportunistic Infections|Renal Transplant|Kidney Transplant|Kidney Diseases |
2022-12-05 |
21% |